Georgiou K, Kolokouris D, Kolocouris A
J Struct Biol X. 2025; 11:100122.
PMID: 40060197
PMC: 11889636.
DOI: 10.1016/j.yjsbx.2025.100122.
Latif K, Ullah A, Shkodina A, Boiko D, Rafique Z, Alghamdi B
Front Pharmacol. 2022; 13:1028356.
PMID: 36386233
PMC: 9643740.
DOI: 10.3389/fphar.2022.1028356.
Thomaston J, Samways M, Konstantinidi A, Ma C, Hu Y, Bruce Macdonald H
Biochemistry. 2021; .
PMID: 34342217
PMC: 8810914.
DOI: 10.1021/acs.biochem.1c00437.
Urata S, Yasuda J, Iwasaki M
Viruses. 2021; 13(5).
PMID: 34068464
PMC: 8150324.
DOI: 10.3390/v13050869.
Raj K, Kaur K, Gupta G, Singh S
Naunyn Schmiedebergs Arch Pharmacol. 2021; 394(7):1383-1402.
PMID: 33961065
PMC: 8102151.
DOI: 10.1007/s00210-021-02091-5.
Antivirals for COVID-19: A critical review.
Frediansyah A, Tiwari R, Sharun K, Dhama K, Harapan H
Clin Epidemiol Glob Health. 2021; 9:90-98.
PMID: 33521390
PMC: 7831805.
DOI: 10.1016/j.cegh.2020.07.006.
Chemical Probes for Blocking of Influenza A M2 Wild-type and S31N Channels.
Tzitzoglaki C, McGuire K, Lagarias P, Konstantinidi A, Hoffmann A, Fokina N
ACS Chem Biol. 2020; 15(9):2331-2337.
PMID: 32786258
PMC: 8051587.
DOI: 10.1021/acschembio.0c00553.
Dysregulation of M segment gene expression contributes to influenza A virus host restriction.
Calderon B, Danzy S, Delima G, Jacobs N, Ganti K, Hockman M
PLoS Pathog. 2019; 15(8):e1007892.
PMID: 31415678
PMC: 6695095.
DOI: 10.1371/journal.ppat.1007892.
Antiviral activity of Poncirus trifoliata seed extract against oseltamivir-resistant influenza virus.
Heo Y, Cho Y, Ju K, Cho H, Park K, Choi H
J Microbiol. 2018; 56(8):586-592.
PMID: 30047088
DOI: 10.1007/s12275-018-8222-0.
Prolidase is required for early trafficking events during influenza A virus entry.
Pohl M, Edinger T, Stertz S
J Virol. 2014; 88(19):11271-83.
PMID: 25031340
PMC: 4178778.
DOI: 10.1128/JVI.00800-14.
Multiscale modeling of influenza A virus infection supports the development of direct-acting antivirals.
Heldt F, Frensing T, Pflugmacher A, Gropler R, Peschel B, Reichl U
PLoS Comput Biol. 2013; 9(11):e1003372.
PMID: 24278009
PMC: 3836700.
DOI: 10.1371/journal.pcbi.1003372.
Solid-supported membrane technology for the investigation of the influenza A virus M2 channel activity.
Balannik V, Obrdlik P, Inayat S, Steensen C, Wang J, Rausch J
Pflugers Arch. 2009; 459(4):593-605.
PMID: 19946785
PMC: 3428792.
DOI: 10.1007/s00424-009-0760-1.
Structure and inhibition of the SARS coronavirus envelope protein ion channel.
Pervushin K, Tan E, Parthasarathy K, Lin X, Jiang F, Yu D
PLoS Pathog. 2009; 5(7):e1000511.
PMID: 19593379
PMC: 2702000.
DOI: 10.1371/journal.ppat.1000511.
The chemical and dynamical influence of the anti-viral drug amantadine on the M2 proton channel transmembrane domain.
Hu J, Fu R, Cross T
Biophys J. 2007; 93(1):276-83.
PMID: 17434944
PMC: 1914427.
DOI: 10.1529/biophysj.106.102103.
Triple antiviral therapy in HCV positive patients who failed prior combination therapy.
Fargion S, Borzio M, Maraschi A, Cargnel A
World J Gastroenterol. 2006; 12(33):5293-300.
PMID: 16981257
PMC: 4088194.
DOI: 10.3748/wjg.v12.i33.5293.
The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging.
McCown M, Pekosz A
J Virol. 2005; 79(6):3595-605.
PMID: 15731254
PMC: 1075690.
DOI: 10.1128/JVI.79.6.3595-3605.2005.
Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial.
Adinolfi L, Utili R, Tonziello A, Ruggiero G
Gut. 2003; 52(5):701-5.
PMID: 12692056
PMC: 1773644.
DOI: 10.1136/gut.52.5.701.
Amantadine's viral kinetics in chronic hepatitis C infection.
Chan J, ORiordan K, Wiley T
Dig Dis Sci. 2002; 47(2):438-42.
PMID: 11855564
DOI: 10.1023/a:1013703013053.
Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture.
Takeda M, Pekosz A, Shuck K, Pinto L, Lamb R
J Virol. 2002; 76(3):1391-9.
PMID: 11773413
PMC: 135863.
DOI: 10.1128/jvi.76.3.1391-1399.2002.
Amantadine inhibits RANTES production by influenzavirus-infected human bronchial epithelial cells.
Asai Y, Hashimoto S, Kujime K, Gon Y, Mizumura K, Shimizu K
Br J Pharmacol. 2001; 132(4):918-24.
PMID: 11181433
PMC: 1572616.
DOI: 10.1038/sj.bjp.0703870.